<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01435460</url>
  </required_header>
  <id_info>
    <org_study_id>634</org_study_id>
    <nct_id>NCT01435460</nct_id>
  </id_info>
  <brief_title>Alrex® Versus Patanol in the Treatment of Seasonal Allergic Conjunctivitis(SAC)</brief_title>
  <official_title>A Clinical Safety and Efficacy Evaluation of Alrex® (Loteprednol Etabonate Ophthalmic Suspension, 0.2%) Versus Patanol (Olopatadine Hydrochloride Ophthalmic Solution, 0.1%) in the Treatment of Seasonal Allergic Conjunctivitis (SAC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bausch &amp; Lomb Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bausch &amp; Lomb Incorporated</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to evaluate the safety and efficacy of Alrex (LE ophthalmic suspension, 0.2%)
      versus Patanol (olopatadine hydrochloride ophthalmic solution, 0.1%) in the temporary relief
      of the signs and symptoms of Seasonal Allergic Conjunctivitis (SAC).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bulbar Conjunctival Injection</measure>
    <time_frame>Change from baseline to day 15 (visit 3)</time_frame>
    <description>Bulbar conjunctival injection (sign) evaluated using a grading scale from 0-3: where 0 = Absent and 3 = Severe</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ocular Itching</measure>
    <time_frame>Change from baseline to day 15 (visit 3)</time_frame>
    <description>Ocular itching (symptom) evaluated using a grading scale from 0-4 where 0 = Absent and 4 = Severe</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bulbar Conjunctival Injection</measure>
    <time_frame>Change from baseline to day 8 (visit 2)</time_frame>
    <description>Bulbar conjunctival injection (sign) evaluated using a grading scale from 0-3: where 0 = Absent and 3 = Severe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ocular Itching</measure>
    <time_frame>Change from baseline to day 8 (visit 2)</time_frame>
    <description>Ocular itching (symptom) evaluated using a grading scale from 0-4 where 0 = Absent and 4 = Severe</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">300</enrollment>
  <condition>Seasonal Allergic Conjunctivitis</condition>
  <arm_group>
    <arm_group_label>Alrex</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ophthalmic formulation containing the active ingredient loteprednol etabonate, 0.2%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patanol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ophthalmic solution containing olopatadine, 0.1%</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Loteprednol etabonate 0.2%</intervention_name>
    <description>1 drop of Alrex 4 times daily (QID) in both eyes at approximately 4 hour intervals for 2 weeks.</description>
    <arm_group_label>Alrex</arm_group_label>
    <other_name>Alrex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olopatadine 0.1%</intervention_name>
    <description>1 drop of Patanol 2 times daily (BID)at intervals of 6-8 hours or more for 2 weeks.</description>
    <arm_group_label>Patanol</arm_group_label>
    <other_name>Patanol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who are diagnosed with acute SAC and experience at least grade 4 ocular
             itching and at least grade 2 bulbar conjunctival injection (redness) in each eye due
             to seasonal allergy at Visit 1.

        Exclusion Criteria:

          -  Subjects who have a known hypersensitivity to the study medications or their
             components or contraindications to ocular corticosteroids.

          -  Subjects who use any of the disallowed medications throughout the duration of the
             study and during the period indicated prior to Visit 1.

          -  Subjects who have intraocular pressure (IOP) greater than 21 mm Hg in either eye or
             any type of glaucoma.

          -  Subjects who have a history of any severe/serious ocular pathology or medical
             condition that could result in the subject's inability to complete the study or affect
             the subject's safety or trial parameters.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Esther Chu</last_name>
    <role>Study Director</role>
    <affiliation>Bausch &amp; Lomb Incorporated</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bausch &amp; Lomb Singapore</name>
      <address>
        <city>Singapore</city>
        <zip>556741</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 14, 2011</study_first_submitted>
  <study_first_submitted_qc>September 15, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2011</study_first_posted>
  <results_first_submitted>February 17, 2012</results_first_submitted>
  <results_first_submitted_qc>February 17, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 13, 2012</results_first_posted>
  <last_update_submitted>February 17, 2012</last_update_submitted>
  <last_update_submitted_qc>February 17, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 13, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ocular allergy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Conjunctivitis</mesh_term>
    <mesh_term>Conjunctivitis, Allergic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Loteprednol Etabonate</mesh_term>
    <mesh_term>Olopatadine Hydrochloride</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Three hundred participants were enrolled in the study. First participant was enrolled 08/03/2010, last participant exited on 04/26/2011. This study was conducted at 7 sites in China.</recruitment_details>
      <pre_assignment_details>Three hundred participants were randomized into two groups, 151 to be treated with Alrex and 149 to be treated with Patanol.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Alrex</title>
          <description>Ophthalmic formulation containing the active ingredient loteprednol etabonate, 0.2%</description>
        </group>
        <group group_id="P2">
          <title>Patanol</title>
          <description>Ophthalmic solution containing olopatadine, 0.1%</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="151"/>
                <participants group_id="P2" count="149"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="140"/>
                <participants group_id="P2" count="143"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did not meet eligibility criteria</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Alrex</title>
          <description>Ophthalmic formulation containing the active ingredient loteprednol etabonate, 0.2%</description>
        </group>
        <group group_id="B2">
          <title>Patanol</title>
          <description>Ophthalmic solution containing olopatadine, 0.1%</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="151"/>
            <count group_id="B2" value="149"/>
            <count group_id="B3" value="300"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.5" spread="14.01"/>
                    <measurement group_id="B2" value="40.6" spread="12.85"/>
                    <measurement group_id="B3" value="40.6" spread="13.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="99"/>
                    <measurement group_id="B2" value="103"/>
                    <measurement group_id="B3" value="202"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Chinese</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="151"/>
                    <measurement group_id="B2" value="149"/>
                    <measurement group_id="B3" value="300"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Bulbar Conjunctival Injection</title>
        <description>Bulbar conjunctival injection (sign) evaluated using a grading scale from 0-3: where 0 = Absent and 3 = Severe</description>
        <time_frame>Change from baseline to day 15 (visit 3)</time_frame>
        <population>Participants analyzed from the per protocol (PP) population</population>
        <group_list>
          <group group_id="O1">
            <title>Alrex</title>
            <description>Ophthalmic formulation containing the active ingredient loteprednol etabonate, 0.2%</description>
          </group>
          <group group_id="O2">
            <title>Patanol</title>
            <description>Ophthalmic solution containing olopatadine, 0.1%</description>
          </group>
        </group_list>
        <measure>
          <title>Bulbar Conjunctival Injection</title>
          <description>Bulbar conjunctival injection (sign) evaluated using a grading scale from 0-3: where 0 = Absent and 3 = Severe</description>
          <population>Participants analyzed from the per protocol (PP) population</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="138"/>
                <count group_id="O2" value="142"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.91" spread="0.521"/>
                    <measurement group_id="O2" value="-1.71" spread="0.585"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Ocular Itching</title>
        <description>Ocular itching (symptom) evaluated using a grading scale from 0-4 where 0 = Absent and 4 = Severe</description>
        <time_frame>Change from baseline to day 15 (visit 3)</time_frame>
        <population>Participants analyzed from the per protocol (PP) population</population>
        <group_list>
          <group group_id="O1">
            <title>Alrex</title>
            <description>Ophthalmic formulation containing the active ingredient loteprednol etabonate, 0.2%</description>
          </group>
          <group group_id="O2">
            <title>Patanol</title>
            <description>Ophthalmic solution containing olopatadine, 0.1%</description>
          </group>
        </group_list>
        <measure>
          <title>Ocular Itching</title>
          <description>Ocular itching (symptom) evaluated using a grading scale from 0-4 where 0 = Absent and 4 = Severe</description>
          <population>Participants analyzed from the per protocol (PP) population</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="138"/>
                <count group_id="O2" value="142"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.74" spread="0.469"/>
                    <measurement group_id="O2" value="-3.28" spread="0.908"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bulbar Conjunctival Injection</title>
        <description>Bulbar conjunctival injection (sign) evaluated using a grading scale from 0-3: where 0 = Absent and 3 = Severe</description>
        <time_frame>Change from baseline to day 8 (visit 2)</time_frame>
        <population>Participants analyzed from the per protocol (PP) population</population>
        <group_list>
          <group group_id="O1">
            <title>Alrex</title>
            <description>Ophthalmic formulation containing the active ingredient loteprednol etabonate, 0.2%</description>
          </group>
          <group group_id="O2">
            <title>Patanol</title>
            <description>Ophthalmic solution containing olopatadine, 0.1%</description>
          </group>
        </group_list>
        <measure>
          <title>Bulbar Conjunctival Injection</title>
          <description>Bulbar conjunctival injection (sign) evaluated using a grading scale from 0-3: where 0 = Absent and 3 = Severe</description>
          <population>Participants analyzed from the per protocol (PP) population</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="140"/>
                <count group_id="O2" value="141"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.36" spread="0.569"/>
                    <measurement group_id="O2" value="-1.18" spread="0.610"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ocular Itching</title>
        <description>Ocular itching (symptom) evaluated using a grading scale from 0-4 where 0 = Absent and 4 = Severe</description>
        <time_frame>Change from baseline to day 8 (visit 2)</time_frame>
        <population>Participants analyzed from the per protocol (PP) population</population>
        <group_list>
          <group group_id="O1">
            <title>Alrex</title>
            <description>Ophthalmic formulation containing the active ingredient loteprednol etabonate, 0.2%</description>
          </group>
          <group group_id="O2">
            <title>Patanol</title>
            <description>Ophthalmic solution containing olopatadine, 0.1%</description>
          </group>
        </group_list>
        <measure>
          <title>Ocular Itching</title>
          <description>Ocular itching (symptom) evaluated using a grading scale from 0-4 where 0 = Absent and 4 = Severe</description>
          <population>Participants analyzed from the per protocol (PP) population</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="140"/>
                <count group_id="O2" value="141"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.46" spread="0.876"/>
                    <measurement group_id="O2" value="-2.02" spread="0.851"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>15 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Alrex</title>
          <description>Ophthalmic formulation containing the active ingredient loteprednol etabonate, 0.2%</description>
        </group>
        <group group_id="E2">
          <title>Patanol</title>
          <description>Ophthalmic solution containing olopatadine, 0.1%</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (11.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Deviated Septum</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>All study data generated as a result of this study will be regarded as confidential, until appropriate analysis and review by the Sponsor or its designee and the Investigator(s) are completed. The results of the study may be published or presented by the Investigator(s)after the review by, and in consultation and agreement with the Sponsor, and such that confidential or proprietary information is not disclosed.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Tuyen Ong</name_or_title>
      <organization>Bausch &amp; Lomb, Incorporated</organization>
      <phone>(973) 360-6389</phone>
      <email>tuyen.ong@bausch.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

